Cite

HARVARD Citation

    Eslami, G. et al. (2020). The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. Journal of antimicrobial chemotherapy. pp. 3366-3372. [Online]. 
  
Back to record